Accelerated phosphatidylcholine turnover in macrophages promotes adipose tissue inflammation in obesity. by Petkevicius, Kasparas et al.
Research article 
 
Accelerated phosphatidylcholine turnover in macrophages promotes adipose 
tissue inflammation in obesity 
 
Authors 
 
Kasparas Petkevicius1, Samuel Virtue1, Guillaume Bidault1, Benjamin Jenkins1, 
Cankut Çubuk3,4,5, Cecilia Morgantini6, Myriam Aouadi6, Joaquin Dopazo3,4,5, Mireille 
Serlie7, Albert Koulman1, and Antonio Vidal-Puig1,2,8 
 
Affiliations 
 
1University of Cambridge Metabolic Research Laboratories, Institute of Metabolic 
Science, MDU MRC. Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK 
 
2Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK 
 
3Clinical Bioinformatics Area, Fundación Progreso y Salud, CDCA, Hospital Virgen del 
Rocio, Sevilla, Spain 
 
4Functional Genomics Node, INB-ELIXIR-es, FPS, Hospital Virgen del Rocio, Sevilla, 
Spain  
 
5Bioinformatics in Rare Diseases (BiER), Centro de Investigación Biomédica en Red 
de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, Sevilla, Spain 
 
6Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, 
Blickagången 6, 141 57 Huddinge, Sweden 
 
7Department of Endocrinology and Metabolism, Amsterdam University Medical 
Center, F5-167, Meibergdreef 9, 1105 AZ, Amsterdam, Netherlands 
 
8Corresponding author 
 
 
  
Abstract 
 
White adipose tissue (WAT) inflammation contributes to the development of insulin 
resistance in obesity. While the role of adipose tissue macrophage (ATM) pro-
inflammatory signalling in the development of insulin resistance has been established, 
it is less clear how WAT inflammation is initiated. Here, we show that ATMs isolated 
from obese mice and humans exhibit markers of increased rate of de novo 
phosphatidylcholine (PC) biosynthesis. Macrophage-specific knockout of 
phosphocholine cytidylyltransferase A (CCTa), the rate-limiting enzyme of de novo PC 
biosynthesis pathway, alleviated obesity-induced WAT inflammation and insulin 
resistance. Mechanistically, CCTa-deficient macrophages showed reduced ER stress 
and inflammation in response to palmitate. Surprisingly, this was not due to lower 
exogenous palmitate incorporation into cellular PCs. Instead, CCTa-null macrophages 
had lower membrane PC turnover, leading to elevated membrane polyunsaturated 
fatty acid levels that negated the pro-inflammatory effects of palmitate. Our results 
reveal a causal link between obesity-associated increase in de novo PC synthesis, 
accelerated PC turnover and pro-inflammatory activation of ATMs. 
  
Introduction 
 
Obesity-related metabolic disorders are among the most prevalent causes of death 
worldwide. Secondary complications of obesity have been suggested to be caused by 
the functional failure of white adipose tissue (WAT), leading to ectopic lipid deposition, 
lipotoxicity and systemic insulin resistance (Virtue and Vidal-Puig, 2010). Obesity is 
associated with a chronic low-grade inflammation, characterised by immune cell 
infiltration to WAT, a switch of adipose tissue macrophage (ATM) polarisation from a 
tissue-remodelling (M2) to a pro-inflammatory (M1) state and elevated production of 
pro-inflammatory, insulin-desensitising cytokines, such as tumour necrosis factor a 
(TNFa). Over the last decade, multiple genetic and pharmacological approaches have 
defined a causal role of macrophage-driven WAT inflammation in the development of 
insulin resistance (Hotamisligil, 2017). However, specific pathophysiological 
mechanisms triggering pro-inflammatory activation of ATMs during obesity are poorly 
understood. 
 
Our previous work identified that the lipid composition of ATMs undergoes both 
quantitative and qualitative changes during obesity (Prieur et al., 2011). Qualitative 
changes in the lipid composition of both plasma and endoplasmic reticulum (ER) 
membranes represent a major factor promoting insulin resistance (Fu et al., 2011; 
Holzer et al., 2011; Wei et al., 2016). Obesity-associated alterations in ER lipid 
composition lead to a cellular process termed ER stress, which invokes an adaptive 
unfolded protein response (UPR) (Hou et al., 2014). In macrophages, the UPR is 
coupled to the activation of intracellular inflammatory signalling pathways that cause 
WAT inflammation and insulin resistance (Robblee et al., 2016; Shan et al., 2017; 
Suzuki et al., 2017). Furthermore, M1 macrophages are characterised by increased 
endogenous fatty acid synthesis, which stabilises lipid rafts within plasma membrane 
to allow pro-inflammatory signal transduction in obesity (Wei et al., 2016). While 
phospholipids (PLs) are the main constituents of plasma and ER membranes, the 
importance of PL biosynthesis in ATMs during obesity has not yet been investigated. 
 
The concept that macrophage ER stress could be induced during obesity due to 
changes in membrane composition is in line with the known physiological changes in 
lipid metabolism that occur during obesity. Obesity is associated with increased 
circulating saturated fatty acids (SFAs), which cause cellular ER stress by being 
incorporated into membrane PLs, leading to a decreased membrane fluidity due to 
increased membrane PL acyl chain saturation. Increased SFA-mediated ER 
rigidification is directly sensed by the transmembrane domains of UPR-transducing 
proteins (Robblee et al., 2016; Volmer et al., 2013). ER saturation and the resulting 
UPR can be counteracted by both endogenously and exogenously derived mono- and 
polyunsaturated fatty acids (MUFAs and PUFAs), and PUFA-containing 
phospholipids, in particular phosphatidylcholines (PCs) (Ariyama et al., 2010; 
Gianfrancesco et al., 2019; Robblee et al., 2016; Rong et al., 2013). 
 
PC is the most abundant PL in mammalian cells. Most cells can synthesise PC de 
novo through the Kennedy pathway, involving the transfer of phosphocholine onto 
diacylglycerol moiety. PCs synthesised de novo predominantly contain saturated 
(SFAs) and monounsaturated fatty acids (MUFAs), while polyunsaturated fatty acids 
(PUFAs) are incorporated into PCs via the Lands cycle, involving a hydrolysis of a 
single fatty acyl chain and esterification of a free PUFA to a resulting 
lysophosphatidylcholine (lysoPC) (Shindou et al., 2013). Metabolic flux through the de 
novo PC synthesis pathway and cellular PC levels are greatly increased in 
differentiating macrophages (Ecker et al., 2010). Furthermore, pro-inflammatory 
signalling via toll-like receptor 4 (TLR4) increases the rate of choline uptake and de 
novo PC synthesis in macrophages (Sanchez-Lopez et al., 2019; Snider et al., 2018; 
Tian et al., 2008). However, de novo PC synthesis in mature macrophages is not 
coupled to the expansion of the cellular PC pool, as it is counteracted by 
phospholipase D activity, leading to a rapid turnover of membrane PCs (Jackowski et 
al., 1997). The consequences of altered PC turnover in metabolic disease are not 
currently known. 
 
Conceptually, the rate of de novo PC synthesis and turnover should affect PC 
remodelling via Lands cycle. The role of the Lands cycle in ER stress function has 
been studied by genetic manipulation of the enzyme lysoPC-acyltransferase 3 
(LPCAT3), the major LPCAT isoform in macrophages (Jiang et al., 2018). LPCAT3 
overexpression increases the rate of PUFA incorporation into PCs and protects cells 
from palmitate-induced ER stress, while the loss of LPCAT3 sensitises cells to 
palmitate lipotoxicity (Rong et al., 2013). 
 
We have previously shown that during obesity, ATMs acquire an M1 phenotype 
concomitantly with their intracellular lipid accumulation (Prieur et al., 2011). Here, we 
demonstrate that markers of de novo PC synthesis are increased in ATMs isolated 
from obese mice and humans. Lepob/ob mice with a myeloid cell-specific reduction in 
de novo PC synthesis rate display reduced adipose tissue inflammation and improved 
metabolic profile compared to controls. Mechanistically, we show that reducing the 
activity of the de novo PC synthesis pathway by 30% does not reduce total cellular PC 
levels in macrophages. Instead, the reduction in PC synthesis is balanced by a 
reduction in PC degradation, maintaining the cellular PC pool size but increasing the 
half-life of PCs. The extended PC half-life leads to increased incorporation of PUFAs 
into PCs by allowing more time for PC remodelling. Elevated PC PUFA content 
protects macrophages from palmitate-induced ER stress and pro-inflammatory 
activation. 
 
  
Results 
 
Obesity accelerates de novo PC biosynthesis in ATMs 
 
In order to identify intrinsic metabolic pathways associated with the phenotypic switch 
of ATMs towards an M1 polarisation state, we reanalysed our published microarray 
dataset (GSE36669) of epididymal WAT (eWAT) macrophages isolated from WT and 
Lepob/ob animals using inferred metabolic flux analysis (Cubuk et al., 2018a; 2018b). 
We focused on the pathways that were unchanged or downregulated in 5-week-old 
Lepob/ob ATMs, which are predominantly M2-polarised, but upregulated at 16 weeks of 
age, when eWAT of Lepob/ob mice is inflamed (Prieur et al., 2011).  Among the 
metabolic pathways that fitted these criteria was de novo PC biosynthesis (Figure 1a-
b), with a lower inferred activity score in 5-week-old, but higher score in 16-week-old 
Lepob/ob ATMs compared to age-matched WT controls (Figure 1d). Further analysis of 
the processes that were unchanged at 5 weeks but upregulated at 16 weeks in Lepob/ob 
ATMs revealed several pathways related to PL metabolism (Figure 1d, Supplementary 
file 1). The activity of de novo PE biosynthesis pathway was not modulated in Lepob/ob 
ATMs (Figure 1-figure supplement 1a-b).  
 
In order to determine whether increased inferred activity of the de novo PC synthesis 
pathway in obesity was specific to ATMs, or also occurred in other tissue-resident 
macrophages, we performed global transcriptomic comparison between liver 
macrophages isolated from 14-week-old Lepob/ob and control mice. Unlike ATMs, liver 
macrophages isolated from obese mice showed similar expression levels of de novo 
PC biosynthesis pathway constituents compared to controls (Figure 1-figure 
supplement 2). 
 
In accordance with our ATM transcriptomic analysis, the expression of Pcyt1a, 
encoding phosphocholine cytidylyltransferase A (CCTa), the rate-limiting enzyme in 
de novo PC synthesis pathway, was unchanged at 5 weeks, but increased at 16 weeks 
in Lepob/ob ATMs compared to WT controls when measured by qPCR (Figure 1e). In 
contrast, the Pcyt1a paralogue Pcyt1b was down-regulated at 5 weeks and not 
modulated at 16 weeks in Lepob/ob ATMs (Figure 1-figure supplement 1c). 
Furthermore, Pcyt1a expression in macrophages isolated from the WAT of obese 
individuals was positively correlated with BMI (Figure 1f). Of note, out of all analysed 
tissue macrophage populations publicly available in Immgen database (Heng et al., 
2008), ATMs had the highest expression of Pcyt1a transcript (Figure 1-figure 
supplement 3). 
 
Next, we reanalysed our previously published lipid profiles from Lepob/ob ATMs (Prieur 
et al., 2011), focusing only on measured PL species. Relative to the total PL amount, 
both PC abundance and PC:PE molar ratio tended to increase (Figure 1-figure 
supplement 4a-b), and palmitate- and stearate-containing lysoPC species were 
upregulated in 16-week-old Lepob/ob ATMs compared to WT controls (Figure 1g). It has 
been previously shown that hepatic lysoPC levels are reduced when the balance 
between PC synthesis and LPCAT activity is perturbed. Specifically, increasing 
LPCAT3 activity without changing de novo PC synthesis or breakdown reduces 
LysoPC levels, as LPCAT3 re-esterifies LysoPC into PC (Rong et al., 2013). 
Conversely, in obese WAT, despite the upregulation of Lpcat3 transcript at both 5 and 
16 weeks in Lepob/ob ATMs (Figure 1-figure supplement 5a), we observed increased 
lysoPC species in Lepob/ob ATMs (Figure 1g). The elevation in LysoPCs was therefore 
consistent with obesity causing a disproportional increase in the rate of both de novo 
PC synthesis and hydrolysis that exceeded the capacity of LPCAT3 to re-esterify Lyso-
PC back into PC (Figure 1-figure supplement 5b).  
 
  
Figure 1 with 5 supplements 
 
De novo PC synthesis rate is increased in ATMs during obesity. 
(A) Simplified schema of the Kennedy pathway of de novo PC biosynthesis. Transcripts in red are 
upregulated in 16-week-old Lepob/ob eWAT macrophages compared to WT controls. 
(B) Normalised microarray gene expression values for the enzymes of the Kennedy pathway of de novo 
PC biosynthesis in eWAT macrophages. 
(C) De novo PC biosynthesis pathway module (M00090) activity in eWAT macrophages, as inferred by 
the Metabolizer algorithm. 
(D) Gene Ontology (GO) pathways related to membrane lipid metabolism that are increased in Lepob/ob 
eWAT macrophages at 16 weeks, but not at 5 weeks of age compared to WT controls. 
(E) Pcyt1a expression in eWAT macrophages, measured by qPCR. 
(F) Pcyt1a expression, measured by qPCR in subcutaneous WAT macrophages isolated from obese 
patients undergoing bariatric surgery, plotted against their body weight (n=19). 
(G) Molar abundance of 16:0 and 18:0 lyso-PC species (expressed as percentage of total measured 
PLs) in eWAT macrophages (n=3 pools of 5 WT, n=6 Lepob/ob mice). 
∗p < 0.05 between genotypes, error bars indicate SEM. 
 
 
Figure 1-figure supplement 1 
 
Obesity does not affect de novo PE synthesis rate in ATMs. 
(A) Normalised microarray gene expression for the enzymes of the Kennedy pathway of de novo PE 
biosynthesis in eWAT macrophages. 
(B) De novo PE biosynthesis pathway module (M00092) activity in eWAT macrophages, as inferred by 
the Metabolizer algorithm. 
(C) Pcyt1b expression in eWAT macrophages, measured by qPCR. 
 
 
Figure 1-figure supplement 2 
 
Obesity does not affect de novo PC synthesis rate in liver macrophages. 
Normalised RNAseq gene expression for the enzymes of the Kennedy pathway of de novo PC 
biosynthesis in liver macrophages, isolated from 14-week-old WT and Lepob/ob mice (n=3). 
 
  
Figure 1-figure supplement 3 
 
Pcyt1a expression levels in different tissue macrophage populations. 
Figure indicating Pcyt1a mRNA levels in isolated tissue macrophage populations, measured by 
RNAseq was obtained directly from Immgen database (www.immgen.org). 
 
 
Figure 1-figure supplement 4 
 
Obesity tends to increase PC molar percentage and PC to PE molar ratio in ATMs. 
(A) PC molar abundance (expressed as percentage of total measured PLs), and (B) PC:PE molar ratio 
in eWAT macrophages (n=3 pools of 5 WT, n=6 16-week-old Lepob/ob mice). 
 
 
  
Figure 1-figure supplement 5 
 
The effects of obesity on PC remodelling gene expression in ATMs. 
(A) Normalised microarray gene expression for the enzymes involved in PC remodelling in eWAT 
macrophages. 
(B) Simplified schema of the interaction between de novo PC synthesis and PC remodelling pathways.  
  
Pcyt1a deletion in myeloid cells improves glucose metabolism in obese mice  
 
To test if increased PC biosynthesis in ATMs affected whole-organism metabolic 
homeostasis, we investigated mice with Pcyt1a deletion in myeloid cells (CCTa mKO) 
that have been described previously (Tian et al., 2008). Initially, we sought to validate 
whether the loss of Pcyt1a would impact macrophage differentiation or function in vitro 
and in vivo. As indicated by the normal surface expression of macrophage markers 
F4/80, CD206 and CD301, unaltered bacterial phagocytosis and normal TNFa and IL-
6 cytokine secretion in response to LPS, the differentiation of CCTa-null bone marrow 
cells into macrophages (BMDMs) was not impaired (Figure 2-figure supplement 1a-
c). Pcyt1a transcript levels in BMDMs on a C57Bl/6J genetic background were 
reduced by ~50%, which translated into ~80% decrease in CCTa protein expression 
and ~30% decrease in de novo PC synthesis rate compared to controls (Figure 2-
figure supplement 1d). In vivo, the expression of macrophage mRNA markers in eWAT 
and liver was comparable between CCTa mKO and control animals (Figure 2-figure 
supplement 2a-b). Overall, these results confirmed that loss of CCTa reduced de novo 
PC biosynthesis rate in macrophages without altering their development or function. 
 
CCTa mKO mice exhibited similar growth rates and metabolic tissue weights 
compared to controls (Figure 2-figure supplement 3a-b). No differences in glucose or 
insulin tolerance tests were observed between CCTa mKO and control groups (Figure 
2-figure supplement 3c-d). In accordance, the expression levels of insulin-regulated 
metabolic genes were similar in eWAT and liver of CCTa mKO and control mice 
(Figure 2-figure supplement 2a-b).  
 
We next evaluated the importance of increased macrophage de novo PC synthesis in 
obesity. We first confirmed that bone marrow transplantation did not alter the induction 
of Pcyt1a in the Lepob/ob genetic background (Figure 2-figure supplement 4). Next, we 
transplanted CCTa mKO or control bone marrow into irradiated Lepob/ob animals 
(Figure 2a). While no differences in post-irradiation body weight gain, WAT and liver 
mass were observed (Figure 2b-c), Lepob/ob mice carrying CCTa mKO bone marrow 
tended to have improved glucose tolerance and exhibited increased sensitivity to 
exogenous insulin compared to controls (Figure 2d-e). Overall, macrophage-specific 
Pcyt1a deletion did not affect ATM development, adipose tissue function and glucose 
metabolism in lean animals, but improved systemic glucose handling in Lepob/ob mice, 
the model of obesity in which we originally observed an induction of Pcyt1a in the ATM 
population. 
 
  
Figure 2 with 4 supplements 
 
Myeloid cell-specific deletion of Pcyt1a leads to improved systemic glucose metabolism on the 
Lepob/ob genetic background. 
(A) Schema of the BMT study design. 
(B) Body weight gain curves and (C) weights of indicated tissues of Lepob/ob mice transplanted with 
Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) bone marrow. 
(D) GTT curves and areas under curve (AUC), normalised to basal glucose levels. 
(E) ITT curves, presented as percentage values of basal glucose levels, and areas above curve (AAC), 
normalised to basal glucose levels. 
 
 
  
Figure 2-figure supplement 1 
 
Myeloid cell-specific deletion of Pcyt1a does not impair BMDM differentiation or function in 
vitro. 
(A) Flow cytometry quantification of macrophage differentiation markers. 
(B) Phagocytosis of E. coli (normalised to control values). 
(C) Cytokine secretion into the medium of BMDMs stimulated with LPS for 6 or 24 hours. 
(D) Pcyt1a expression, CCTa protein levels and 3H-choline incorporation rate into membrane lipids. 
Pcyt1afl/fl (n=4) or Pcyt1afl/fl Lyz2Cre/+ (n=4) BMDMs. 
 
 
Figure 2-figure supplement 2  
 
Myeloid cell-specific deletion of Pcyt1a does not affect eWAT or liver gene expression in lean 
mice. 
Normalised expression of indicated genes in (A) eWAT and (B) liver of Pcyt1afl/fl (n=7) or Pcyt1afl/fl 
Lyz2Cre/+ (n=9) animals on a C57Bl/6J genetic background, measured by qPCR. 
 
 
  
Figure 2-figure supplement 3 
 
Myeloid cell-specific deletion of Pcyt1a does not affect growth or glucose metabolism of lean 
mice. 
(A) Body weight gain curves and (B) tissue weights of lean mice. 
(C) GTT curves and areas under curve (AUC), normalised to basal glucose levels. 
(D) ITT curves, presented as percentage values of basal glucose levels, and areas above curve (AAC), 
normalised to basal glucose levels. 
 
 
Figure 2-figure supplement 4 
 
WT to Lepob/ob bone marrow transplant does not affect the increase of Pcyt1a transcription in 
eWAT ATMs. 
Pcyt1a expression measured by qPCR in eWAT macrophages isolated from WT and Lepob/ob mice 
carrying WT bone marrow at 18 weeks of age (n=7 mice/group).  
Pcyt1a deletion in myeloid cells alleviates inflammation and improves insulin 
signalling in the WAT of obese mice  
 
While the metabolic effects of macrophage-specific Pcyt1a deletion on a Lepob/ob 
background were modest, they were consistent with the relatively small reduction 
(30%) in de novo PC biosynthesis rate we observed in BMDMs in vitro. We next sought 
to determine how Pcyt1a deficiency in macrophages improved glucose metabolism in 
obese mice. First, we performed whole transcriptome comparison of eWAT isolated 
from CCTa mKO Lepob/ob BMT and control animals. Pathway analysis of the 
transcriptomic data revealed an increase in transcripts associated with insulin 
sensitivity and glucose metabolism, while pathways related to ER stress and 
macrophage-driven inflammation were supressed in CCTa mKO compared to control 
BMT Lepob/ob mice (Figure 3a, Supplementary files 2a-b). RNA sequencing results 
were also confirmed by qPCR (Figure 2-figure supplement 1a). In accordance to gene 
expression data, insulin-responsive AKT phosphorylation was increased in the eWAT 
of CCTa mKO Lepob/ob animals compared to controls (Figure 3b-c). Furthermore, while 
we found no differences in total ATM number, eWAT macrophages showed a shift 
from M1 to M2 polarisation in CCTa mKO compared to controls (Figure 3d). No 
differences in the number of crown-like structures (CLS) and eWAT adipocyte area 
were observed between genotypes (Figure 3-figure supplement 2a-c). Finally, unlike 
eWAT, the expression of pro-inflammatory and insulin-responsive marker genes in the 
liver were similar between genotypes (Figure 2-figure supplement 1b). Similarly, 
insulin-responsive AKT phosphorylation was comparable between the livers of both 
genotypes (Figure 3-figure supplement 3a-b) and only tended to be increased in the 
skeletal muscles of CCTa mKO compared to control BMT Lepob/ob mice (Figure 3-
figure supplement 3c-d), indicating that macrophage-specific Pcyt1a deletion had a 
stronger impact on white adipose tissue insulin signalling, compared to liver and 
muscle. Altogether, we have found that reducing de novo PC biosynthesis rate in 
macrophages alleviates WAT inflammation and insulin resistance in obese mice, 
without affecting total ATM and CLS number. 
 
  
Figure 3 with 3 supplements 
 
Myeloid cell-specific deletion of Pcyt1a leads to reduced WAT inflammation on the Lepob/ob 
genetic background. 
(A) Selected pathways from eWAT RNAseq analysis, upregulated (red) or downregulated (blue) in 
Lepob/ob mice transplanted with Pcyt1afl/fl Lyz2Cre/+ (n=8) bone marrow compared to controls (n=7). 
(B) Representative AKT phosphorylation Western blots and (C) their densitometry quantification in 
eWAT of Lepob/ob mice transplanted with Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) bone marrow. 
(D) Flow cytometry gating strategy, quantification of ATM number per gram of eWAT and the relative 
polarisation of ATM population in Lepob/ob mice. 
 
 
  
Figure 3-figure supplement 1 
 
The effects of myeloid cell-specific deletion of Pcyt1a on eWAT and liver gene expression on 
the Lepob/ob genetic background. 
Relative expression of indicated genes in the (A) eWAT and (B) liver of Lepob/ob BMT mice, measured 
by qPCR. 
 
Figure 3-figure supplement 2 
 
Myeloid cell-specific deletion of Pcyt1a does not affect eWAT CLS number or adipocyte size on 
the Lepob/ob genetic background. 
(A) Representative histology images of eWAT sections of Lepob/ob BMT mice, CLS are marked in red. 
Quantification of (B) CLS and (C) average adipocyte area in the eWAT sections of Lepob/ob BMT mice. 
 
  
Figure 3-figure supplement 3 
  
The effects of myeloid cell-specific deletion of Pcyt1a on liver and skeletal muscle AKT 
signalling on the Lepob/ob genetic background. 
Representative AKT phosphorylation Western blots and their densitometry quantification in (A, B) liver 
and (C, D) gastrocnemius muscle of Lepob/ob mice transplanted with Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ 
(n=8) bone marrow. 
  
 
Loss of Pcyt1a lowers palmitate-induced ER stress and inflammation in 
macrophages 
 
Next, we sought to investigate the molecular events that reduce WAT inflammation in 
obese animals carrying CCTa mKO bone marrow. For this purpose, we utilised an in 
vitro model of BMDMs exposed to high palmitate concentrations. We selected 
palmitate concentrations that have previously been reported to induce ER stress and 
pro-inflammatory activation, thus mimicking the effects of obesity on ATMs (Robblee 
et al., 2016). We observed diminished Tnf transcript levels in palmitate-treated CCTa-
null macrophages compared to controls (Figure 4a). Reduced inflammation in BMDMs 
was accompanied by a lower ER stress response to palmitate, as indicated by lower 
induction of ER stress marker gene expression and reduced stress-responsive kinase 
activation in CCTa-null BMDMs compared to controls (Figure 4b-d).  
 
Furthermore, CCTa-null BMDMs were less susceptible to palmitate-induced cell death 
than controls (Figure 4-figure supplement 1a). While Pcyt1a deficiency was protective 
against cytotoxicity in response to palmitate, it was detrimental in response to other 
ER stressors, including thapsigargin (Figure 4-figure supplement 1b) and free 
cholesterol (Zhang et al., 2000). Finally, cultured peritoneal macrophages isolated 
from CCTa mKO animals also showed reduced ER stress response to palmitate 
compared to controls (Figure 4-figure supplement 2). Overall, CCTa-null 
macrophages were protected against palmitate-induced ER stress and subsequent 
cytotoxicity and inflammation. 
 
  
Figure 4 with 2 supplements 
 
Pcyt1a deficiency protects macrophages from palmitate-induced ER stress and inflammation. 
(A) Tnf expression levels in Pcyt1afl/fl (n=5) or Pcyt1afl/fl Lyz2Cre/+ (n=3) BMDMs treated with indicated 
doses of palmitate for 16 hours. 
(B) Fold induction (compared to BSA alone) of indicated ER stress marker gene expression Pcyt1afl/fl 
(n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs treated with 250 µM palmitate for 16 hours. 
(C) Representative Western blots and (D) their densitometry quantification of Pcyt1afl/fl (n=5) or 
Pcyt1afl/fl Lyz2Cre/+ (n=3) BMDMs treated with indicated doses of palmitate for 16 hours. 
∗p < 0.05 between genotypes, error bars indicate SEM. All presented experiments are representative 
of at least 3 BMDM cultures. 
 
 
Figure 4-figure supplement 1 
 
Pcyt1a deficiency protects macrophages from palmitate, but not thapsigargin-induced cell 
death. 
Flow cytometry quantification of dead Pcyt1afl/fl (n=4) or Pcyt1afl/fl Lyz2Cre/+ (n=4) BMDMs treated with 
indicated doses of (A) palmitate or (B) 150 nM thapsigargin for 16 hours.  
 
Figure 4-figure supplement 2 
 
Pcyt1a deficiency protects peritoneal macrophages from palmitate-induced ER stress. 
ER stress marker gene expression in cultured peritoneal macrophages from Pcyt1afl/fl (n=4) or Pcyt1afl/fl 
Lyz2Cre/+ (n=8) treated with 250 µM palmitate for 16 hours. 
  
De novo PC biosynthesis pathway does not incorporate exogenous palmitate 
into membrane PCs  
 
We next investigated how mitigating CCTa activity caused a reduction in palmitate-
induced ER stress. As the de novo PC biosynthesis pathway had been suggested to 
control the flux of exogenous palmitate into cellular PCs (Robblee et al., 2016), we 
hypothesised that CCTa-null BMDMs would have a reduced rate of palmitate 
incorporation into their membranes. In order to test our hypothesis, we traced the 
incorporation of exogenous palmitate into cellular PCs over time. Surprisingly, CCTa-
null and control BMDMs showed no differences in the rate of radiolabelled palmitate 
appearance in total lipid or PC fractions (Figure 5a-b).  
 
We then attempted to validate our unexpected findings using acute pharmacological 
inhibition of CCTa by miltefosine. Miltefosine reduced the rate of de novo PC synthesis 
in palmitate-treated BMDMs in a dose-response manner (Figure 5c). In contrast, only 
100 μM concentration of miltefosine showed an inhibitory effect on the incorporation 
of palmitate into membrane PCs (Figure 5c). Importantly, and in line with the evidence 
from our genetic model, the dose of miltefosine that reduced de novo PC biosynthesis 
rate by 30% (as we have observed in CCTa-null BMDMs, Figure 2-figure supplement 
1d) had no effect on the rate of incorporation of exogenous palmitate into cellular PCs 
in BMDMs (Figure 5c). 
 
It has been proposed that the Kennedy pathway is coupled to endogenous cellular 
fatty acid synthesis (Ecker et al., 2010; Ridgway and Lagace, 2003). In accordance, 
acetate incorporation into cellular PCs and total lipids showed a similar fold decrease 
(approximately 30%) as the reduction in de novo PC synthesis rate in CCTa-null 
macrophages (Figure 5d-e). Overall, we found that reducing the rate of de novo PC 
synthesis in macrophages proportionally decreased the rate of incorporation of lipids 
derived from de novo lipogenesis, which are known to be incorporated by the Kennedy 
pathway, but did not affect the rate of exogenous palmitate incorporation into 
membrane lipids.  
 
  
Figure 5 with no supplements 
 
Pcyt1a deficiency in macrophages does not affect the rate of exogenous palmitate incorporation 
into PCs. 
(A) Representative autoradiogram and densitometry quantification of 14C-palmitate incorporation into 
PCs or (B) total lipids of Pcyt1afl/fl (n=4) or Pcyt1afl/fl Lyz2Cre/+ (n=4) BMDMs treated with 250 µM 
palmitate for indicated periods of time. 
(C) Inhibition of de novo PC biosynthesis (red line) and 14C-palmitate incorporation into PC fraction 
(blue line) of WT BMDMs (n=4), pretreated with indicated doses of miltefosine for 1 hour and stimulated 
with 250 µM palmitate for 3 hours. Representative autoradiogram is presented below. 
(D) Representative autoradiogram and densitometry quantification of 14C-acetate incorporation into 
PCs or (E) total lipids of untreated Pcyt1afl/fl (n=4) or Pcyt1afl/fl Lyz2Cre/+ (n=4) BMDMs over 3 hours, 
normalised to Pcyt1afl/fl group average. 
∗p < 0.05 between genotypes, error bars indicate SEM. All presented experiments are representative 
of at least 3 BMDM cultures. 
 
 
 
 
  
Loss of Pcyt1a in macrophages increases membrane PUFA abundance that 
protects against palmitate-induced ER stress 
 
As our tracer experiments could not explain the diminished ER stress response 
observed in CCTa-null BMDMs in response to palmitate, we performed global 
lipidomic analysis of CCTa-null and control BMDMs. As described previously (Tian et 
al., 2008), total quantities of PC and PE in macrophages were unaffected by Pcyt1a 
deletion (Figure 6-figure supplement 1a). Unexpectedly, CCTa-null macrophages 
showed an enrichment in PUFA-containing PC levels compared to controls (Figure 
6a, Figure 6-source data 1). Consistent with such observation, the expression of sterol 
regulatory element-binding protein 1 (SREBP1) target genes, which are known to be 
downregulated by high levels of PUFA-containing PLs in the ER (Hagen et al., 2010), 
was lower in CCTa-null macrophages than controls (Figure 6-figure supplement 2). 
Furthermore, changes in PE composition were similar to qualitative PC changes in 
CCTa-null and control cells (Figure 6-figure supplement 1b), indicating that reducing 
de novo PC biosynthesis rate promotes PUFA accumulation in membrane PLs. 
 
We observed similar levels of saturated PC species between CCTa-null and control 
BMDMs in under basal conditions (Figure 6b). Interestingly, the increased abundance 
of PUFA-containing PCs in CCTa-null BMDMs was at the expense of decreased 
mono- and diunsaturated PC species (Figure 6a-b). We confirmed these findings by 
analysing total BMDM fatty acid composition, which showed increased relative 
abundance of arachidonic (20:4n6), docosapentaenoic (22:5n6) and docosahexanoic 
acids (22:6n3), while palmitoleic and oleic acid levels were reduced in CCTa-null cells 
compared to controls (Figure 6c). 
 
As expected, palmitate treatment caused a large increase in the abundance of 
saturated PC species in BMDMs (Figure 6-figure supplement 3b). Interestingly, in 
palmitate-treated macrophages, PC saturation was increased mostly at the expense 
of reduced mono- and diunsaturated PCs, while the proportion of 3 or more double 
bond-containing PC species was largely unaffected by palmitate treatment (Figure 6b 
and figure supplement 3b). Consequently, CCTa-null BMDMs showed higher 
membrane PUFA levels than controls even after prolonged treatment with palmitate, 
leading to diminished palmitate-induced PC saturation (Figures 6b and figure 
supplement 4). Prolonged palmitate treatment elevated PC:PE ratio to a similar extent 
in both CCTa-null and control BMDMs, suggesting that changes in total PC levels or 
PC:PE ratio were unlikely to explain differences in ER stress response between 
genotypes (Figure 6-figure supplement 3a). 
 
Our lipidomics analysis demonstrated that reduced CCTa activity could affect the 
levels of fatty acids other than palmitate and specifically resulted in the preferential 
accumulation of long chain PUFAs. These results were consistent with increased 
remodelling of PCs, most likely by LPCAT3. Furthermore, our lipid analysis also 
suggested an explanation for the lower ER stress in response to palmitate. 
Considerable literature has demonstrated that increased PUFA content in cellular 
membranes is protective against palmitate induced ER stress (Rong et al., 2013; Yang 
et al., 2011), suggesting a mechanistic explanation for the protective effects of Pcyt1a 
deletion against palmitate toxicity.  
 
In order to experimentally demonstrate that CCTa-null macrophages exhibited lower 
ER stress in response to palmitate due to qualitative changes in membrane PL 
composition, we performed a rescue experiment of palmitate-treated BMDMs using 
exogenous arachidonic acid. Compared to palmitate treatment alone, 10:1 molar 
mixture of palmitate and arachidonate reduced Tnf and ER stress marker gene 
expression to the same basal level in both CCTa-null and control BMDMs (Figure 6d), 
suggesting that elevated PUFA levels negate the inflammatory effects of palmitate in 
macrophages lacking Pcyt1a. Overall, our results were consistent with a loss of CCTa 
resulting in a shift to a PUFA-rich membrane fatty acid composition that was protective 
against exogenous palmitate. 
 
  
Figure 6 with 4 supplements 
 
Pcyt1a deficiency increases PUFA-containing PC levels in macrophages. 
(A) Volcano plot of indicated PC species, expressed as molar percentage of all measured PCs, in 
Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs. 
(B) Pie charts indicating the relative abundance of PC species with different degrees of unsaturation in 
Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs in a basal state or after 16-hour treatment with 250 
µM palmitate. 
(C) Volcano plot of indicated fatty acid species, expressed as molar percentage of all measured fatty 
acids, in Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs. 
(D) Fold induction (compared to BSA alone) of indicated ER stress marker gene and Tnf expression in 
Pcyt1afl/fl (n=4) or Pcyt1afl/fl Lyz2Cre/+ (n=4) BMDMs after 16-hour treatment with 250 µM palmitate, 
supplemented with or without 25 µM arachidonate.  
 
  
Figure 6-figure supplement 1 
 
The effects of Pcyt1a deficiency on total PC and PE levels and PE composition in macrophages. 
(A) Abundance of all detected PC and PE species in Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs 
in a basal state. 
(B) Volcano plot of indicated PE species, expressed as molar percentage of all measured PEs, in 
Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs in a steady state. 
 
 
Figure 6-figure supplement 2 
 
Pcyt1a deficiency reduces SREBP1 target gene expression in macrophages. 
Normalised expression of SREBP1 target genes in Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs 
in a basal state. 
 
 
  
Figure 6-figure supplement 3 
 
 
The effects of palmitate treatment on PC to PE ratio and PC composition in macrophages. 
(A) PC to PE molar ratio in Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs in a basal state or after 
16-hour treatment with 250 µM palmitate. 
(B) Volcano plot of indicated PC species, expressed as molar percentage of all measured PCs, in 
Pcyt1afl/fl (n=7) BMDMs treated with BSA or 250 µM palmitate for 16 hours.  
 
 
 
Figure 6-figure supplement 4 
 
 
Pcyt1a deficiency increases total PUFA levels in macrophages.  
Relative abundance of indicated fatty acids in Pcyt1afl/fl (n=7) or Pcyt1afl/fl Lyz2Cre/+ (n=8) BMDMs in a 
basal state or after 16-hour treatment with 250 µM palmitate. 
 
 
Figure 6-source data 1. A list of all measured lipid species by LC-MS in Pcyt1afl/fl (n=7) or Pcyt1afl/fl 
Lyz2Cre/+ (n=8) BMDMs in a basal state or after 16-hour treatment with 250 µM palmitate. Peak areas 
for each lipid were normalised to the peak areas of a respective internal standard and expressed as 
peak area ratios. 
 
  
Reduced PC turnover promotes membrane PUFA accumulation in Pcyt1a-
deficient macrophages 
 
Finally, we set out to explain how reduced CCTa activity could lead to an alteration in 
the fatty acid composition of PC. Our hypothesis was that the increased half-life of 
membrane PCs in CCTa-null macrophages might allow more time for PCs to be 
remodelled to contain PUFAs via the Lands cycle. CCTa-null macrophages have 
previously been shown to have reduced PC turnover rates without changes in total PC 
levels (Tian et al., 2008) and our experimental findings confirmed these results, as we 
have observed reduced de novo PC synthesis rate and unchanged PC abundance in 
CCTa-null BMDMs compared to controls (Figure 2-figure supplement 1d and Figure 
6-figure supplement 1a).  
 
We next sought to confirm that the increased levels of PUFAs in CCTa-null 
macrophages were due to a lower turnover of PC. To do so, we performed a pulse-
chase experiment using 3H-arachidonic acid. Indeed, CCTa-null BMDMs had 
increased retention of arachidonic acid in their membranes compared to control cells 
(Figure 7a). Overall, our results showed that the rate of PC turnover in macrophages 
is negatively associated with PUFA retention in PLs.  
 
Importantly, while the data from Pcyt1a-deficient models demonstrated lower PC 
turnover, increased levels of long-chain PUFAs and lower PUFA turnover rates, this 
data came from congenic models lacking Pcyt1a. To exclude this being a phenomenon 
unique to genetically manipulating Pcyt1a, we sought to manipulate PC turnover rates 
via an alternative route. To do so, we pharmacologically blocked PC hydrolysis by 
inhibiting phospholipase D activity using 1-butanol. In accordance with our hypothesis, 
reducing PC turnover by inhibiting PC conversion to phosphatidic acid phenocopied 
the effects of reduced CCTa activity on cellular membrane fatty acid composition 
(Figure 7b). 
 
  
Figure 7 with no supplements 
 
Reduced PC turnover increases membrane PUFA levels in macrophages. 
(A) 3H-arachidonate levels in Pcyt1afl/fl (n=4) or Pcyt1afl/fl Lyz2Cre/+ (n=4) BMDMs, pulsed with tracer 
amounts of 3H-arachidonate for 16 hours and chased with medium for indicated periods of time. 
(B) Linear regression analysis of the correlation between fold changes in the molar fatty acid percentage 
induced by genetic Pcyt1a deletion (n=4) and by PLD inhibition using 15 µM 1-butanol for 24 hours 
(n=4). 
  
Discussion 
 
Here, we demonstrate for the first time that obesity is characterised by an increase in 
de novo PC synthesis pathway in ATMs. We show that the increase in ATM de novo 
PC biosynthesis during obesity is pathophysiological using a macrophage-specific 
genetic model of reduced CCTa activity. Reducing de novo PC synthesis rate in ATMs 
alleviates obesity-induced WAT inflammation and improves systemic glucose 
metabolism. Mechanistically, we show that decreasing CCTa activity in macrophages 
does not reduce PC levels, but instead leads to a compensatory reduction in PC 
degradation and maintenance of normal PC levels. Because of this reduced PC 
turnover, more time is afforded for PC remodelling enzymes to act on PCs, leading to 
an increase in PUFA-containing PC species that are protective against ER stress in 
response to palmitate. Our results reveal a novel relationship between the regulation 
of de novo PC synthesis, PC turnover and membrane saturation. 
 
Our study extends on existing findings regarding the importance of CCTa in mediating 
SFA-induced lipotoxicity in cultured macrophages. Two recent independent reports 
have suggested that de novo PC synthesis is responsible for exogenous palmitate 
incorporation into membrane PCs (Gianfrancesco et al., 2019; Robblee et al., 2016). 
Robblee et al. based their conclusions on data obtained from pharmacologically 
inhibiting CCTa using miltefosine at a dose of 100 μM, which inhibits de novo PC 
synthesis rate to a level that also leads to a reduction in exogenous palmitate 
incorporation, a result we reproduce here (Figure 5C). However, lower doses of 
miltefosine reduce de novo PC synthesis rate without affecting palmitate incorporation 
into cell membranes. At 25 μM mitefosine, we detect a 30% reduction in de novo PC 
synthesis rate with no reduction in palmitate incorporation, which phenocopies our 
genetic model of Pcyt1a deficiency in BMDMs. Importantly, our data show that a 30% 
reduction in de novo PC synthesis rate is sufficient to ameliorate ER stress, 
highlighting the capacity for changes in PC biosynthetic rate to regulate ER stress in 
a manner that does not require changes in palmitate incorporation. In this publication, 
we describe such a mechanism; that of reduced CCTa activity leading to increased 
PC half-life and thus permitting the establishment of a membrane composition that is 
protective against palmitate-induced ER stress. Similarly, Gianfrancesco et al have 
utilised siRNA-mediated PCYT1A knockdown in cultured human macrophages to 
achieve approximately 50% reduction in de novo PC synthesis rate and demonstrated 
that it reduces SFA-induced inflammation. Due to a lack of tracer experiment in their 
study, we believe that reduced IL-1b secretion in their PCYT1A knockdown model is 
due to increased membrane PUFA content, as our experimental findings demonstrate 
that at 50 μM mitefosine, we detect a 50% reduction in de novo PC synthesis rate with 
no significant reduction in palmitate incorporation. 
 
Further support for a role of PC turnover in regulating ER stress comes from recent 
work investigating TLR4 signalling. It has recently been shown that palmitate is not a 
direct TLR4 agonist, but instead requires TLR4 activation-induced changes in 
intracellular metabolism in order to promote ER stress and inflammation in 
macrophages (Lancaster et al., 2018). Importantly, it has previously been 
demonstrated that TLR4 activation increases the rate of de novo PC synthesis and 
PC turnover in macrophages in order to provide a supply of new membranes for 
secretory vesicle formation in Golgi apparatus (Sanchez-Lopez et al., 2019; Snider et 
al., 2018; Tian et al., 2008). As such, our findings are in line with a mechanism in which 
basal TLR4 activation increases sensitivity of cells to palmitate by increasing PC 
turnover. In support of this concept, we demonstrate that decreasing de novo PC 
synthesis protects macrophages from palmitate-driven ER stress and inflammation. 
Furthermore, two recent reports have demonstrated that TLR4 activation in 
macrophages increases the transcription of Slc44a1, encoding choline transporter 
CTL1 (Sanchez-Lopez et al., 2019; Snider et al., 2018).  As we observed increased 
Slc44a1 transcript levels in Lepob/ob ATMs compared to controls, in future it will be of 
interest to test whether the increase in Pcyt1a transcript in ATMs isolated from obese 
mouse and human WAT is dependent on TLR4 activation.  
 
While ATMs undergo pro-inflammatory activation during obesity, liver macrophages 
do not (Morgantini et al., 2019). It is likely that for this reason we observed an 
increased de novo PC synthesis pathway activity in ATMs, but not in liver 
macrophages isolated from Lepob/ob mice. While speculative, the absence of pro-
inflammatory activation and normal de novo PC synthesis rate in liver macrophages 
could explain why hepatic genes related to metabolism and inflammation were 
comparable between CCTa-null Lepob/ob BMT and control mice. 
 
The observed effect size of macrophage-specific Pcyt1a deletion on systemic insulin 
sensitivity on the Lepob/ob genetic background is relatively small. This could potentially 
be explained by two factors: 1) relatively small decrease (30%) in de novo PC 
synthesis rate in Lyz2Cre/+ Pcyt1afl/fl macrophages, due to the poor penetrance of 
Lyz2Cre/+ on Pcyt1a allele, as described previously (Zhang et al., 2000); 2) 
Macrophage-specific Pcyt1a deletion having a stronger impact on white adipose tissue 
insulin sensitivity, compared to muscle and liver. In either case, our data demonstrates 
a link between the increase in de novo PC biosynthesis rate in ATMs and the 
development of adipose tissue inflammation and insulin resistance. 
 
Finally, inactivating mutations in PCYT1A gene have been linked to several human 
pathologies, including retinal dystrophy, spondylometaphyseal dysplasia and 
lipodystrophy (Hoover-Fong et al., 2014; Payne et al., 2014; Yamamoto et al., 2014). 
Our results suggest that besides controlling the production of bulk cellular PC mass, 
CCTa activity can affect the fatty acid composition of cell membranes by regulating 
their turnover, thus potentially explaining why homozygous PCYT1A mutations 
manifest in specific tissue disorders, and not in a systemic failure of proliferating cells. 
Such specificity is also reflected in our CCTa-null Lepob/ob BMT model, where Pcyt1a 
deletion altered the inflammatory profile of ATMs, but not liver macrophages. In future, 
it would be interesting to study the relative impact of Pcyt1a deletion on different cell 
types, as well as same cell types present in different tissue microenvironments. 
 
  
Materials and methods 
 
Key Resources Table 
Reagent type 
(species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
information 
genetic reagent 
(M. musculus, 
male) 
Lepob/ob The 
Jackson 
Laboratory 
IMSR Cat# 
JAX:000632, 
RRID:IMSR_J
AX:000632 
 
genetic reagent 
(M. musculus) 
Lyz2Cre/+ Clausen et 
al, 1999 
IMSR Cat# 
JAX:004781, 
RRID:IMSR_J
AX:004781 
Lyz2tm1(cre)Ifo; 
Donated by Dr. 
Susan 
Jackowski 
genetic reagent 
(M. musculus) 
Pcyt1afl/fl Zhang et 
al, 2000 
IMSR Cat# 
JAX:008397, 
RRID:IMSR_J
AX:008397 
Pcyt1atm1Irt;  
Donated by Dr. 
Susan 
Jackowski 
antibody anti-CD45 BD 
Bioscience
s 
564279, RRID
:AB_2651134 
Flow cytometry 
(1:200) 
antibody anti-CD11b BD 
Bioscience
s 
564443, RRID
:AB_2722548 
Flow cytometry 
(1:200) 
antibody anti-SiglecF BD 
Bioscience
s 
562757, RRID
:AB_2687994 
Flow cytometry 
(1:200) 
antibody anti-F4/80 BioLegend 123116, RRID
:AB_893481 
Flow cytometry 
(1:200) 
antibody Anti-F4/80 
(IHC) 
Bio-Rad Cl:A3-1, 
RRID:AB_110
2558 
IHC(1:100) 
antibody anti-CD206 BioLegend 141723, RRID
:AB_2562445 
Flow cytometry 
(1:200) 
antibody anti-CD11c BioLegend 117336, RRID
:AB_2565268 
Flow cytometry 
(1:200) 
antibody anti-Ly6G BioLegend 127608, RRID
:AB_1186099 
Flow cytometry 
(1:200) 
antibody anti-CD301 BioLegend 145704, RRID
:AB_2561961 
Flow cytometry 
(1:200) 
antibody anti-CCTa Abcam ab109263, 
RRID:AB_108
59965 
WB(1:1000 
dilution in 3% 
milk TBS-T), 
4℃ overnight 
antibody anti-beta 
Actin 
Abcam ab8227, 
RRID:AB_230
5186 
WB(1:1000 
dilution in 3% 
milk TBS-T), 
4℃ overnight 
antibody anti-P-
Thr183/Tyr1
85 JNK  
Cell 
signalling 
9251, 
RRID:AB_331
659 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody anti-JNK Cell 
signalling 
9252, 
RRID:AB_225
0373 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody anti-P-
Thr180/Tyr1
82 p38 
MAPK  
Cell 
signalling 
4511L, 
RRID:AB_213
9679 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody anti-p38 
MAPK 
Cell 
signalling 
9212, 
RRID:AB_330
713 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody Anti-P-
Ser473 AKT 
Cell 
signalling 
4060, 
RRID:AB_231
5049 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody Anti-P-
Thr308 AKT 
Cell 
signalling 
9275, 
RRID:AB_329
828 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody Anti-pan 
AKT 
Cell 
signalling 
9272, 
RRID:AB_329
827 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
antibody Anti-GAPDH Cell 
signalling 
97166, 
RRID:AB_275
6824 
WB(1:1000 
dilution in 3% 
BSA TBS-T), 
4℃ overnight 
sequence-based 
reagent 
List of 
nucleotide 
sequences 
This paper PCR primers See Table S3 
for the full list of 
qPCR primer 
sequences 
commercial 
assay or kit 
Alpha Trak 2 
glucose 
meter 
Zoetis N/A  
commercial 
assay or kit 
TruSeq 
Stranded 
mRNA 
Library Prep 
(96 
Samples) 
Illumina 20020595  
commercial 
assay or kit 
Vybrant 
Phagocytosi
s Assay Kit 
Thermofis
her 
V-6694  
commercial 
assay or kit 
RNeasy Mini 
Kit (250) 
Qiagen 74106  
chemical 
compound, drug 
Insulin Novo 
Nordisk 
EU/1/02/230/
003 
 
chemical 
compound, drug 
STAT 60 AMS 
Biotech 
CS-502  
chemical 
compound, drug 
Reverse 
Transcriptas
e M-MLV 
Promega M170b  
chemical 
compound, drug 
M-MLV RT 
5x buffer 
Promega M351A  
chemical 
compound, drug 
MgCl2 
25mM 
Promega A351B  
chemical 
compound, drug 
Random 
Primers 
Promega C118A  
chemical 
compound, drug 
dNTP Mix 
10 mM 
Promega U151B  
chemical 
compound, drug 
Chlorofom Sigma 34854  
chemical 
compound, drug 
Methanol Sigma 34860  
chemical 
compound, drug 
BF3 
Methanol 
Sigma B1127  
chemical 
compound, drug 
Hexane Sigma 34859  
chemical 
compound, drug 
Ammonium 
formate 
Sigma 516961  
chemical 
compound, drug 
Acetonitrile VWR 83640.320  
chemical 
compound, drug 
1-butanol Sigma 281549  
chemical 
compound, drug 
Miltefosine Sigma M5571  
chemical 
compound, drug 
Arachidonic 
acid 
Cayman 90010  
chemical 
compound, drug 
Palmitic acid Cayman 1000627  
chemical 
compound, drug 
[1-14C]- 
palmitic acid 
Perkin 
Elmer 
NEC075H050
UC 
 
chemical 
compound, drug 
[1,2-14C]- 
acetic acid, 
sodium salt 
Perkin 
Elmer 
NEC553250U
C 
 
chemical 
compound, drug 
Methyl-[3H]- 
choline 
chloride 
Perkin 
Elmer 
NET109250U
C 
 
chemical 
compound, drug 
[5,6,8,9,11,1
2,14,15-
3H(N)]-
arachidonic 
acid 
Perkin 
Elmer 
NET298Z050
UC 
 
chemical 
compound, drug 
Bovine 
Serum 
Albumin 
Sigma A8806 BSA used for 
cell culture 
experiments 
chemical 
compound, drug 
Hionic-Fluor 
scintillation 
liquid  
Perkin 
Elmer 
6013319  
chemical 
compound, drug 
Opti-Fluor 
scintillation 
liquid  
Perkin 
Elmer 
6013199  
chemical 
compound, drug 
Ethanol Sigma 459836  
chemical 
compound, drug 
DAKO Real 
Peroxidase 
Blocking 
solution 
Agilent S2023  
chemical 
compound, drug 
MOM 
ImmPress 
Polymer 
Reagent 
Vector MP-2400  
chemical 
compound, drug 
DAB 
Peroxidase 
(HRP) 
Substrate Kit 
Vector SK-4100  
chemical 
compound, drug 
Dako REAL 
Haematoxyli
n 
Agilent S2020  
software, 
algorithm 
Metabolizer 
algorithm 
Cubuk et 
al, 2018 
n/a http://metaboliz
er.babelomics.o
rg 
software, 
algorithm 
MassHunter 
Workstation 
Software 
Quantitative 
Analysis 
(Version 
B.07.00) 
Agilent 
Technologi
es Inc 
n/a  
software, 
algorithm 
Thermo 
Xcalibur 
Quan 
browser 
integration 
software 
(Version 3.0) 
Thermofis
her 
n/a  
software, 
algorithm 
HALO AI Indica 
Labs 
n/a  
software, 
algorithm 
TopHat 
(Version 
2.0.11) 
Kim et al., 
2013 
RRID:SCR_0
13035 
 
software, 
algorithm 
EdgeR Robinson 
et al., 
2010 
RRID:SCR_0
12802 
 
software, 
algorithm 
HiPathia Hidalgo et 
al., 2017 
n/a http://hipathia.b
abelomics.org 
 
 
  
Mice 
All animal protocols were conducted in accordance with the UK Home Office and 
Cambridge University ethical guidelines. Mice were housed 3-4 per cage in a 
temperature-controlled room (21°C) with a 12 h light/dark cycle, with ‘lights on’ 
corresponding to 6 am. Animals had ad-libitum access to food and water. A standard 
chow diet (DS-105, Safe Diets) was administered to all animals from weaning, 
consisting of 64.3% carbohydrate, 22.4% protein and 13.3% lipid of total calories. Only 
male mice were used for in vivo experiments. Male and female mice (8-20 weeks of 
age) were used for in vitro BMDM cultures. 
 
Generation of myeloid cell-specific CCTa KO mouse 
Macrophage-specific Pcyt1a knockout mouse (CCTa mKO) was generated by 
crossing a mouse model containing loxP sequences surrounding Pcyt1a alleles 
(Pcyt1afl/fl) to the Lyz2Cre/+ (Clausen et al., 1999) mouse. Pcyt1afl/fl mouse was 
generated by Prof. Ira Tabas and Dr. Susan Jackowski as described (Zhang et al., 
2000), and was gifted to us on a mixed C57Bl/6J, 129/Sv genetic background by 
Dr. Suzanne Jackowski. Pcyt1afl/fl and Lyz2Cre/+ lines were backcrossed to a C57Bl/6J 
genetic background using Marker-Assisted Accelerated Backcrossing (MAX-BAX, 
Charles River, UK) technology until SNP genotyping confirmed >99% background 
purity. 
 
All experimental macrophage-specific knockout mice were produced by crossing 
Lyz2+/+ with Lyz2Cre/+ animals on a floxed/floxed background, yielding a 1:1 Mendelian 
ratio of control (floxed/floxed Lyz2+/+) to knockout (floxed/floxed Lyz2Cre/+) offspring. 
 
Bone marrow transplant 
4-6-week-old WT or Lepob/ob host mice for bone marrow transplant were purchased 
from Jackson laboratories and were allowed to acclimatise for at least 2 weeks before 
the experiment. At 8 weeks of cage, mice were split into two groups of equal average 
body weight and equal average fed blood glucose concentration (Respective BW and 
glucose values ±SEM for control and CCTa mKO BMT: 47.1±0.78 g and 46.8+1.68 g, 
p=0.87; 27.9±3.05mM and 24,4+3.46mM, p=0.45). All mice were given 1% Baytril 
antibiotic in drinking water a day before irradiation. All mice received two doses of 5.5 
Gy of radiation using Caesium 60 source. Two hours post irradiation, donor bone 
marrow cells (13 million/mouse) were injected into the tail veins of the irradiated mice. 
The cells from one donor mouse were used for up to 2 host mice. Host mice were then 
housed at 3-4/cage, with 1-2 mice carrying Pcyt1afl/fl bone marrow and 1-2 - Pcyt1afl/fl 
Lyz2Cre/+ bone marrow in each cage. Mice were kept on 1% Baytril for 1 month, 
monitored and weighed regularly until 12 weeks of age. A single Lepob/ob mouse 
carrying Pcyt1afl/fl bone marrow had to be culled due to health reasons. Mice were 
then housed under standard housing conditions throughout the duration of the study. 
 
 
Cells 
 
Culture and differentiation of bone-marrow derived macrophages 
Femur and tibia bones from mice were isolated and cleaned, and 10 ml of Roswell 
Park Memorial Institute Medium (RPMI)-1640 (Sigma) was flushed through each bone 
using a syringe. Bone marrow cells were counted manually, pelleted by centrifugation, 
and re suspended in RPMI-1640 with 20-30% L929 conditioned medium, 10% heat-
inactivated FBS (Gibco, Thermofisher Scientific) and 100 U/ml penicillin- streptomycin 
(Thermofisher Scientific) (macrophage differentiation medium). To differentiate into 
macrophages, cells were seeded in 10 cm non-culture treated plates (Falcon) at a 
density of 5x106 cells per plate per 10 ml of macrophage differentiation medium and 
cultured for 7 days at 37 °C in 5% CO2. On day 5 of differentiation, medium was 
removed, and 10 ml of fresh macrophage differentiation medium was added to each 
plate. On day 7 of differentiation, macrophages were detached using ice-cold PBS 
containing 1 mM EDTA, counted using Countess automated cell counter 
(Thermofisher), centrifuged at 500 g, room temperature for 5 min and re suspended 
in macrophage differentiation medium at the concentration of 5x105 cells/ml. 
Immediately after, cells were plated for experiments at the following densities: 500 
µl/well of 24-well plate, 1 ml/well of 12-well plate, 2 ml/well of 6-well plate and 10 ml 
per 10 cm plate. Cells were incubated for at least 24 h after plating before conducting 
experiments.  
 
To make L929 conditioned medium, L929 cells (CCL-1, ATCC) were seeded in DMEM 
supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin-streptomycin and 2 
mM L-glutamine (Sigma) at a density of 500,000 cells per 50 ml of medium per T175 
tissue culture flask. Medium was harvested after 1 week of culture, and then 50 mL of 
fresh DMEM supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin-
streptomycin and 2 mM L-glutamine was added onto cells and harvested 1 week later. 
Batches obtained after the first and second weeks of culture were mixed at a 1:1 ratio, 
aliquoted and stored at -20 °C. 
 
Isolation and culture of peritoneal macrophages 
Immediately after sacrifice, 5 ml of PBS containing 3% FBS was injected into palpitate 
peritoneal cavity. As much liquid as possible was recovered, and the procedure was 
repeated two more times with fresh PBS containing 3% FBS. Pooled lavages were 
centrifuged at 400 g, 4 °C for 5 min. Cells were resuspended in 1 ml DMEM 
supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin-streptomycin and 2 
mM L-glutamine (Sigma) and counted manually. The concentration was adjusted to 
5x105 cells/ml, and cells were plated in 24-well plates with 500 µl of cell 
suspension/well. Medium was changed after 6 hours, and cell stimulations were 
performed the following day. 
 
Isolation of liver macrophages 
Liver macrophages were isolated according to a previously published detailed method 
(Aparicio-Vergara et al., 2017). Briefly, livers of anesthetized mice were first perfused 
with calcium-free Hanks` balanced salt solution (HBSS), followed by collagenase 
digestion. After digestion, the hepatocytes were released by mechanical dissociation 
of the lobes and underwent several steps of filtration with calcium-containing HBSS 
and centrifugation at 50g for 3 min. The supernatant containing non-parenchymal cells 
was loaded on a Percoll gradient (25% and 50%) and centrifuged for 30 min, at 2300 
rpm, at 4°C. The interphase ring with enriched LMs was collected. The cells were then 
plated for 30 min and washed twice before RNA was extracted for subsequent 
analyses. 
 
Human adipose tissue biopsies 
Subcutaneous adipose tissue biopsies were collected from 19 individuals undergoing 
bariatric bypass surgery, and adipose tissue macrophages were isolated. The 
metabolic parameters of individuals have been published earlier (de Weijer et al., 
2013). The isolation of macrophages from these adipose tissue biopsies has been 
described and presented earlier (Virtue et al., 2015). 
  
Methods 
 
Glucose tolerance tests 
Mice were fasted for 16 h from 4 pm to 8 am. Mice were single-housed at least 1 h 
prior to being injected intraperitoneally with 1 mg/kg glucose. Blood samples for 
glucose measurement were taken at indicated times after the injection. 
 
Insulin tolerance tests 
Mice were fasted for 6 h from 8 am to 2 pm. Mice we single-housed at least 1 h prior 
to being injected intraperitoneally with 0.75 IU/kg of human insulin. Insulin dose of 2.5 
IU/kg was used for Lepob/ob mice.  Blood samples for glucose measurement were taken 
at indicated times after the injection. 
 
Isolation of stromal-vascular fraction (SVF) from WAT 
Adipose tissues were removed after sacrifice, chopped thoroughly and resuspended 
in 10 ml digestion solution containing 7 ml Hanks’ Balanced Salt Solution (HBSS, 
H9269, Sigma), 0.23 g bovine serum albumin (BSA, A8806, Sigma), and 20 mg 
collagenase type II (C6885, Sigma), filtered through 0.22 μm membrane. The 
digestion was performed at 37°C for 20 min, with horizontal shaking at 100 rpm. The 
digestion mixture was then passed through a 100 µm cell strainer (352360, Falcon) 
into a fresh tube and incubated at room temperature for 10 min, allowing the adipocyte 
fraction to layer on the surface. Adipocyte fraction was removed by pipetting. The 
remaining solution was centrifuged at 400 g, 4° for 5 min and pellet was re suspended 
in 1 ml of pre-cooled (at 4°C) FACS buffer (PBS, 1mM EDTA, 3% heat-inactivated 
FBS). Total SVF cell number was determined by Countess automated cell counter 
(Thermofisher). 
 
Flow cytometry 
SVF or BMDMs were collected and kept in FACS buffer (PBS, 1mM EDTA, 3% HI-
FBS) on ice. Cell were stained with LIVE/DEAD (Invitrogen) and non-specific binding 
was blocked with 5 μg/ml anti-CD16/32. Cell surfaces were then stained with anti-
CD45, anti-CD11b, anti-Siglec-F, anti-F4/80, anti-CD301, anti-CD206, anti-CD11c. 
Cells were gated within the live single cell population as CD45+/Ly6g-/SiglecF-
/CD11b+/F4/80+ for ATMs. For BMDMs, median fluorescence for indicated markers 
was measured in live single cell population. Data were acquired on LSRFortessa (BD 
Biosciences) using FACS Diva software and analysed with TreeStar FlowJo (Version 
vX0.7). 
 
Phagocytosis 
Bacterial phagocytosis in BMDMs was measured by incubating cells for 2 hours with 
E. coli (K-12 strain) bacteria, labelled with the fluorescent dye fluorescein, according 
to manufacturer’s protocol (Vybrant™ Phagocytosis Assay Kit, ThermoFisher). 
 
Radioisotope labelling 
For radiolabelling experiments, radioisotope tracers were dissolved in macrophage 
differentiation medium at the following concentrations: 0.074 MBq/ml for methyl-[3H] 
choline chloride (for PC synthesis assays), 0.06 MBq/ml for [1-14C]-palmitic and [3H]-
arachidonic acids, and 0.148 MBq/ml for [1-14C] acetic acid. BMDMs were plated at 
the standard densities in 24-well plates for PC synthesis and fatty acid 
incorporation/chase assays and in 6-well plates for lipid class analysis by thin-layer 
chromatography. 
 
Radioactivity in total cells was determined by lysing cells in 100 µl of PBS containing 
1% TritonTM X-100, adding the lysate to scintillation vial containing 5 ml of Hionic-Fluor 
scintillation liquid and subjecting it to liquid scintillation counting (LSC). 
 
Fatty acid treatments 
All fatty acid treatments were done using FFAs conjugated to BSA (fatty acid and 
endotoxin free, A8806, Sigma). The conjugation was performed by preparing a sterile-
filtered 5% BSA solution in macrophage differentiation medium. Both 5% BSA medium 
and concentrated fatty acid solution (100 mM of fatty acid in ethanol) were heated at 
60°C before adding fatty acid solution dropwise into 5% BSA medium in order to make 
a medium containing 2.5 mM fatty acid and 5% BSA (approximately 10:3 fatty acid to 
BSA molar ratio). This medium was then sonicated until it became completely clear 
and used as a stock solution for stimulations on the same day without sterile filtering. 
FFA-free BSA solution with equivalent amount of ethanol was used as a control. In 
dose-response experiments, the amount of BSA and ethanol in each condition was 
adjusted to the highest dose of palmitate. Unless otherwise indicated, fatty acid 
treatments were performed overnight for 16 hours. 
 
Extraction and quantification of RNA 
RNA from cells was extracted using RNeasy Plus Mini kit (74106, Qiagen) following 
manufacturers’ instructions. 30 μl of RNAse-free water was used for elution.  
 
RNA from tissues was harvested by adding 1 ml of RNA Stat-60 reagent (Tel Test) to 
approximately 100 mg of frozen tissue placed in a Lysing Matrix D tube (MP 
Biomedicals). Samples were homogenised using a FastPrep homogeniser (MP 
Biomedicals) for 2 x 45 s at 5.5 m/s and centrifuged at 14,000 g for 5 min to pellet 
debris. The aqueous phase was transferred to a fresh tube containing 200 μl 
chloroform. Samples were mixed and centrifuged at 14,000 g, 4°C for 15 min. The 
clear upper phase containing RNA was removed and precipitated by mixing it with 500 
μl isopropanol and incubating at room temperature for 10 min. Samples were 
centrifuged at 14,000 g, 4°C for 10 min and supernatants were discarded. RNA pellets 
were then washed with 70% ethanol, air-dried and re-suspended in 100 μl of RNAse-
free water. 
 
RNA concentration and purity were determined using Nanodrop ND-1000 
spectrophotometer (Thermofisher Scientific). The absorbance was measured at 260 
nm against RNAse-free water. A single A260 unit was assumed to be equal to 40 
μg/mL of RNA. All RNA samples were stored at -80°C for subsequent processing. 
 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Complementary DNA (cDNA) was generated using Promega reagents in a 20 μl 
reaction as follows: 500 ng RNA was added to 1 x M-MLV reverse transcriptase master 
mix (M351A) with 2.5 mM MgCl2 (A351B), 1.25 mM dNTPs (U151B), and 5 μg/mL 
random hexamers (C118A), and denatured at 65°C for 5 min before being transferred 
directly to ice in order to prevent the reassembly of the secondary structures of RNA. 
After the addition of 1 μL of M-MLV reverse transcriptase (M170b), the reaction was 
incubated at 37°C for 1 h for cDNA synthesis and 95°C for 5 min for enzyme 
denaturation. cDNA was diluted 75-fold in RNAse-free water and stored at -20°C. 
 
qRT-PCR was performed in a 13 μL reaction with 5 μl of diluted cDNA, 6.5 μl of 2x 
TaqMan or SYBR Green reagent (Applied Biosystems), 1.3 μl of 3 mM forward and 
reverse primer mix (including 1.5 mM of probe for TaqMan reactions) and 0.2 μl of 
RNAse-free water according to the default manufacturer’s protocol (Applied 
Biosystems). Primer sequences are listed in Supplementary file 3. Reactions were run 
in duplicate for each sample and quantified using the ABI Prism 7900 sequence 
detection system (Applied Biosystems). Duplicates were checked for reproducibility, 
and then averaged; ‘no reverse transcriptase’ controls were included to check for 
genomic DNA contamination, and ‘no template’ controls were included to check for 
the formation of primer dimers. Product specificity was determined using a dissociation 
curve for SYBR green reactions. A standard curve generated from a pool of all cDNA 
samples was used for quantification. The expression of genes of interest was 
normalized using BestKeeper method to the geometric average of 3-4 housekeeping 
genes (for mouse: 18s, 36b4 and Tbp; for human: Actb, B2m, Gapdh and Polr2a), and 
data was expressed as arbitrary units or normalised to the average of control group. 
 
Whole adipose tissue RNA sequencing and analysis 
2 µg of eWAT RNA was used to generate barcoded sequencing libraries using 
TruSeq® Stranded mRNA Library Preparation Kit (Illumina) following manufacturer’s 
instructions. After adjusting for concentration, the sequencing libraries were combined 
into 96-plex pools. The pooled libraries were sequenced on 3 lanes of an Illumina 
HiSeq 4000 instrument at single-end 50bp (SE50), yielding an average of 15.7 million 
reads per sample. Library preparation was performed by the Genomics and 
Transcriptomic Core at the Institute of Metabolic Science. The sequencing was 
performed at the Genomics Core, Cancer Research UK Cambridge Institute.  
 
RNA sequencing data was aligned using TopHat (V2.0.11) to the mouse GRCm38 
genome and genes were counted using HTseq-count (V0.8.0) by the Genomics and 
Transcriptomic Core at the Institute of Metabolic Science. Data normalisation and 
differential gene expression analysis was performed with edgeR using TMM and 
generalized linear model methods, respectively. Pathway activity analysis was 
performed using HiPathia algorithm. 
 
Extraction of RNA, RNA sequencing and analysis of liver macrophages 
RNA extraction was performed using the TRIzol Reagent according to the 
manufacturer’s instructions (15596018, ThermoFisher).  
 
RNA libraries were prepared using TruSeq® Stranded mRNA kit (Illumina). The 
concentration of indexed libraries was quantified by RT–qPCR using the Universal 
Kapa Library Quantification Kit (KAPA Biosystems). Final libraries were normalized 
and sequenced on an Illumina HiSeq 2000 sequencer.  
 
Raw fastq-files were aligned against the murine genome version mm10 using TopHat 
(v2.0.13) with all default options. BAM files containing the alignment results were 
sorted according to the mapping position. mRNA quantification was performed using 
FeatureCounts from the Subread package against the GRCm38-gencode transcripts 
database version seven (gencode.vM7.annotation.gtf) and the GRCh38-genocode 
transcripts database version 24 (gencode.v24.annotation.gtf) to obtain read counts for 
each individual Ensembl gene. The read count table of the dataset was normalized 
separately using DESeq2. 
 
Protein extraction and quantification 
BMDMs were treated as described in legend, washed once with ice-cold PBS and 
lysed in ice-cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 
0.5% sodium deoxycholate, 1% NP-40, pH 7.4) containing PierceTM protease and 
phosphatase inhibitors (88668, Thermofisher Scientific). 150 µl of RIPA buffer was 
used to lyse 106 cells. Frozen white adipose tissue, liver and gastrocnemius muscle 
samples (approximately 50 mg) were ground in liquid nitrogen using mortar and pestle, 
and powdered tissue was then dissolved in 200 µl ice-cold RIPA buffer. Lysates were 
collected and centrifuged at 14,000 g, 4°C for 10 min to remove cell debris.  
 
Protein concentration was determined by DC Protein assay (5000111, Biorad) 
according to manufacturer’s instructions. 
 
Western blotting 
Protein lysates were diluted in NuPAGETM LDS sample buffer (NP0007, Thermofisher 
Scientific) containing 2.5% 2-mercaptoethanol and boiled at 95°C for 5 min. 10 μg of 
protein was then separated by electrophoresis using NuPAGETM SDS-polyacrylamide 
gels (Thermofisher Scientific) and transferred to nitrocellulose membranes using the 
iBlot® Dry Blotting System (Thermofisher Scientific). Membranes were blocked for 1 
h in 5% fat-free milk (Marvel) or 5% BSA in Tris-buffered saline containing 0.05% 
Tween (TBST) at room temperature and incubated overnight at 4°C with the 
appropriate primary antibody. Bound primary antibodies were detected using 
peroxidase-coupled secondary anti-rabbit antibody (7074, Cell signalling) and 
enhanced chemiluminescence (WBLUF0500, Millipore). Blots were exposed digitally 
using the ChemiDoc MP System (Bio-Rad), and bands were quantified using Image 
Lab™ software (Bio-Rad). The expression of proteins was normalised to a 
housekeeping protein (β-actin), and the phosphorylation status was determined by 
normalising to a respective total protein. All protein quantification data is expressed as 
arbitrary units. 
 
Adipose tissue histology and imaging 
Adipose tissue samples for histology were placed in 10% formalin overnight, then 
transferred to 70% ethanol before embedding in paraffin. Different 4 µm sections were 
obtained from FFPE blocks and extra-coated with paraffin to preserve tissue integrity. 
 
After incubating overnight at 37°C, sections were dewaxed using xylene and 100% 
industrial methylated spirits, then washed under running water for 5 min and kept in 
TBST. The sections were stained as follows: 1) blocking endogenous peroxidases for 
5 min (DAKO Real Peroxidase Blocking solution, S2023); 2) wash in TBST; 3) blocking 
using serum for 20 min; 4) primary anti-F4/80 antibody incubation for 60 min; 5) wash 
in TBST for 5 min; 6) 30 min incubation with MOM ImmPress Polymer Reagent (MP-
2400); 7) wash in TBST; 8) DAB solution (5-10 minutes) prepared according to the 
manufacturer’s instruction (DAB Peroxidase substrate kit,  SK-4100); 9) wash in 
TBST; 10) 1 min incubation with Dako REAL Haematoxylin (S2020).  The sections 
where then washed in tap water, dehydrated in graded alcohols, cleared in xylene and 
mounted. 
 
All eWAT slides were scanned using a Zeiss Axio Scan Z1 and analysed using HALO 
software (Indica Labs, Corrales, NM). The ‘tissue classifier module’, utilising a state-
of-the-art machine learning algorithm to identify tissue types based on colour, texture, 
and contextual features, was used to distinguish areas containing F4/80-positive cells 
(marked in dark green). ‘Vacuole Quantification module’ was then applied to analyse 
the adipocytes in dark green areas and in a whole section. Intact vacuoles completely 
surrounded by F4/80-positive cells were considered as CLS, while whole section 
vacuole analysis was used to determine average adipocyte area. The analyses were 
performed on the whole section to avoid selection bias; tissue edges were excluded 
using manual annotation. Halo was “trained-by-example” on randomly selected 
images, and then the analysis was extended on the whole batch of sections with HALO 
automated pipeline. 
 
Lipid extraction 
Total lipids from cells were extracted using a modified Folch extraction method. Glass 
pipettes were used throughout the procedure in order to avoid plastic-bound lipid 
contamination. 1 ml of HPCL-grade chloroform: methanol 2:1 v/v mixture was added 
to cell samples in a glass vial. Where applicable, appropriate amounts (calculated by 
approximating the average abundance of every fatty acid within the sample and adding 
matching amounts of standard) of 1,2-diundecanoyl-sn-glycero-3-phosphocholine 
(phospholipid standard, 850330C, Sigma) were included in extraction mixture as 
internal standard. Samples were homogenised by vortexing for 15 s. 200 μl of HPLC-
grade water was added to each sample before vortexing for 2 min and centrifuging at 
4000 g for 10 min. 700 μl of the lower lipid fraction was transferred to a 7 ml glass 
tube. A second extraction was performed by adding 700 μl of fresh HPLC-grade 
chloroform followed by vortexing and centrifugation as above. 900 μl of lower lipid 
fraction was collected and pooled with the first 700μl fraction (total 1600 μl). Collected 
lipid fractions were dried under nitrogen stream. Dried lipids were stored at -20°C for 
subsequent processing, or resuspended in 100 µl chloroform, transferred to 
scintillation vials containing 5 ml of Opti-Fluor scintillation liquid (6013199, Perkin 
Elmer) and subjected to LSC.   
 
Thin-layer chromatography 
BMDMs were treated in 6-well plates as indicated in legend and lipids were labelled 
as described. Lipids from cells were extracted and solubilised in 50 µl of HPLC-grade 
chloroform. 20 µl of lipids were then spotted at the bottom of 20 cm x 20 cm thin layer 
chromatography (TLC) silica plates (Z292974, Sigma). TLC plates were placed into 
hermetic glass chambers containing 250 ml of 65:25:4 chloroform: methanol: 
ammonium hydroxide v/v solution for phospholipid separation. Plates were allowed to 
develop until the solvent front was approximately 2 cm below the top of the plate. 
Plates were dried under laminar flow and incubated with radiographic films (47410, 
Fujifilm) in the dark for 1-3 days at room temperature. Radiographic films were 
developed using automated film developer and scanned. ImageJ software (NIH) was 
used to calculate the density of the bands on scanned radiograms. 
 
LC-MS lipid analysis 
To the previously dried lipid samples, 60 µL of the lipid internal standard was added 
(methanol containing CE(18:0)d6, Ceramide(16:0)d31, FA(15:0)d29, LPC(14:0)d42, 
PA(34:1)d31, PC(34:1)d31, PE(34:1)d31, PG(34:1)d31, PI(34:1)d31, PS(16:0)d62, 
SM(16:0)d31, TG(45:0)d29, and TG(54:0)d35, all at 10 µg/mL). The samples were then 
thoroughly vortexed, then dried under a gently stream of nitrogen. The samples were 
then reconstituted by adding 740 µL of 4:1 mix of isopropanol and acetonitrile, 
respectively, and vortexed ensuring there was no undissolved material. The samples 
were then analysed by LC-MS analysis. 
 
Chromatographic separation was achieved using Acquity UPLC CSH C18 (50 mm x 
2.1 mm, 1.7 µm) LC column with a Shimadzu UPLC system (Shimadzu UK Limited, 
Wolverton, Milton Keynes). The column was maintained at 55 oC with a flow rate of 
0.5 mL/min. A binary mobile phase system was used with mobile phase A; 60:40 
acetonitrile to water, respectively, with 10 mM ammonium formate, and mobile phase 
B; 90:10 isopropanol to acetonitrile, respectively, with 10 mM ammonium formate. The 
gradient profile was as follows; at 0 minutes_40% mobile phase B, at 0.4 minutes_43% 
mobile phase B, at 0.45 minutes_50% mobile phase B, at 2.4 minutes_54% mobile 
phase B, at 2.45 minutes_70% mobile phase B, at 7 minutes_99% mobile phase B, at 
8 minutes_99% mobile phase B, at 8.3 minutes_40% mobile phase B, at 10 
minutes_40% mobile phase B.  
 
Mass spectrometry detection was performed on an Exactive Orbitrap mass 
spectrometer (Thermo Scientific, Hemel Hempstead, UK) operating in 
positive/negative ion switching mode. Heated electrospray source was used, the 
sheath gas was set to 40 (arbitrary units), the aux gas set to 15 (arbitrary units) and 
the capillary temperature set to 300 °C. The instrument was operated in full scan mode 
from m/z 150–1200 Da. 
 
Data processing was completed using Thermo Xcalibur Quan browser integration 
software (Thermo Scientific, Hemel Hempstead, UK). The identification of the lipid 
species was determined by an MS-signal for the corresponding theoretically 
calculated m/z accurate mass found at the expected retention time. The semi-
quantitation of the lipids was calculated by the integration of the analyte MS-signal 
relative to the lipid class internal standard concentration. 
 
Quantitative analysis of fatty acid methyl esters (FAMEs) 
In order to derive FFAs and esterified fatty acids from complex lipids into FAMEs, 750 
μl of HPLC-grade chloroform: methanol 1:1 v/v solution was added to previously dried 
lipids in 7 ml glass vials. 125 μl of 10% boron trifluoride in methanol (134821, Sigma) 
was then added into each vial. Vials were sealed and incubated in an oven at 80°C 
for 90 min in order to hydrolyse fatty acid-glycerol and fatty acid-cholesterol ester 
bonds and form FAMEs. Samples were allowed to cool, and 1 ml of HPLC-grade n-
Hexane and 500 μl of HPLC-grade water were added. Samples were briefly vortexed 
and centrifuged at 2000 g using benchtop centrifuge. The upper organic layer was 
transferred into 2 ml gas chromatography glass vials and dried under nitrogen stream. 
 
Gas chromatography-mass spectrometry was performed with Agilent 7890B gas 
chromatography system linked to Agilent 5977A mass spectrometer, using AS3000 
auto sampler. A TR-FAME column (length: 30 m, inter diameter: 0.25 mm, film size: 
0.25 μm, 260M142P, Thermofisher Scientific) was used with helium as carrier gas. 
Inlet temperature was set at 230°C. Dried FAME samples were re-suspended in 100 
µl HPLC-grade n-Hexane. 1 µl of this solution was injected for analysis. The oven 
programme used for separation was as follows: 100°C hold for 2 min, ramp at 
25°C/min to 150°C, ramp at 2.5°C/min to 162°C and hold for 3.8 min, ramp at 
4.5°C/min to 173°C and hold for 5 min, ramp at 5°C/min to 210°C, ramp at 40°C/min 
to 230°C and hold for 0.5 min. Carrier gas flow was set to constant 1.5 ml/min. If the 
height of any FAME peaks exceeded 108 units, sample was re-injected with 10:1 – 
100:1 split ratio. Identification of FAME peaks was based on retention time and made 
by comparison with those in external standards (Food industry FAME mix, 35077, 
Restek).  
 
Peak integration and quantification was performed using MassHunter Workstation 
Quantitative Analysis software (version B.07.00, Agilent). Specific high-abundance 
ions from total ion chromatogram were chosen to calculate each fatty acid peak. The 
values for each fatty acid were expressed in molar percentages by dividing the area 
of each peak by the sum of all peak areas for a given sample. This analysis accounted 
for differences in total lipid content between samples. 
 
Statistical analysis and graphical representation of data 
All data from experiments is represented as a mean, with error bars showing standard 
error of the mean and the number of replicates stated in legend. Some data is 
represented as a fold-change, and it is stated in legend to what value the data 
represented was normalised to generate the fold-change. Statistical tests used are 
also stated in legend. A student’s t-test was used to compare two groups; one-way 
analysis of variance (ANOVA) was used to compare more than 2 groups, followed by 
Bonferonni’s post-hoc test. Where more than one factor influenced the variable being 
measured, 2-way ANOVA was used to test for a significant effect of each factor as 
well as an interaction between factors. 
 
All statistical tests were performed and graphs were generated using GraphPad Prism 
6 software. Graphs and figures were edited for presentation using Adobe Illustrator 
CC 2015 software. 
 
Metabolizer algorithm used to analyse microarray data can be accessed at 
http://metabolizer.babelomics.org and its methodology is presented in recent 
publications (Cubuk et al., 2018b; 2018a). 
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